Acute ischemic stroke update

Pharmacotherapy

Volumn 30, Issue 5, 2010, Pages 493-514

  Baldwin, Kathleen ^a   Orr, Sean ^a   Briand, Mary ^a   Piazza, Carolyn ^a   Veydt, Annita ^a   McCoy, Stacey ^a  

^a BAPTIST MEDICAL CENTER   (United States)

Author keywords

Acute ischemic stroke; AIS; Neurology; Pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ARGATROBAN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CITICOLINE; CLOPIDOGREL; D DIMER; DESMOTEPLASE; EPTIFIBATIDE; FIBRINOGEN; GELATINASE B; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LABETALOL; LISINOPRIL; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM; MEVINOLIN; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID; PLACEBO; PROTEIN S100B; TENECTEPLASE; TIROFIBAN; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR; WARFARIN;

ACUTE DISEASE; BLEEDING; BLOOD PRESSURE REGULATION; BRAIN DECOMPRESSION; BRAIN EDEMA; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CAROTID ENDARTERECTOMY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRANIECTOMY; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; GLYCEMIC CONTROL; GOLD STANDARD; HEADACHE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHERMIA; INDUCED HYPOTHERMIA; INFECTION; INFLAMMATION; INJURY SCALE; LOW DRUG DOSE; NEUROPROTECTION; PATIENT CARE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPEECH DISORDER; STENT; THROMBECTOMY; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS INFECTION; VISUAL IMPAIRMENT; WEAKNESS;

ACUTE DISEASE; ANIMALS; BRAIN ISCHEMIA; EMERGENCY TREATMENT; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77951825990     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.5.493     Document Type: Review

References (91)

1. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial - TOAST, trial of Org 10172 in acute stroke treatment. Stroke 1993;24:35-41.
2. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999;30:2513-2516
3. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-1711
4. Gruber A. Interventional management of stroke. Stroke 2008;39:1663-1664
5. National Institute of Neurological Disorders and Stroke. NINDS CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) information page. Available from http://www.ninds.nih.gov/ disorders/cadasil/CADASIL.htm. Accessed October 13, 2009.
6. Hacke W, Kaste M, Bluhmki E, et al, for the ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329
7. Foerch C, Montaner J, Furie KL, Ning MM, Lo EH. Invited article: searching for oracles? Blood biomarkers in acute stroke. Neurology 2009;73:393-399
8. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the biomarker rapid assessment in ischemic injury (BRAIN) study. Stroke 2009;40:77-85.
9. Polderman KH, Herold I. Therapeutic hypothermia and controlled normothermia in the intensive care unit: practical considerations, side effects, and cooling methods. Crit Care Med 2009;37:1101-1120
10. Rerkasem K, Rothwell PM. Systematic review of the operative risks of carotid endarterectomy for recently symptomatic stenosis in relation to the timing of surgery. Stroke 2009;40: e564-72.
11. Zaidat OO, Klucznik R, Alexander MJ. The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology 2008;70:1518-1524
12. Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a special writing group of the American Heart Association stroke council and the council on cardiovascular disease in the young. Stroke 2008;39:2644-2691
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-2497
14. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis [online exclusive article]. BMJ 2005;330:342. Available from http://www.bmj.com/cgi/content/full/330/7487/342?view= long&pmid=15640250.
15. Jamieson DG, Skliut M. Gender considerations in stroke management. Neurologist 2009;15:132-141
16. Pezzini A, Del Zotto E, Giossi A, Volonghi I, Grassi M, Padovani A. The migraine-ischemic stroke connection: potential pathogenic mechanisms. Curr Mol Med 2009;9:215-226
17. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354. (Erratum in Circulation 2007;116:e138.)
18. Emsley HC, Smith CJ, Tyrrell PJ, Hopkins SJ. Inflammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit Care 2008;9:125-138
19. Welsh P, Lowe GD, Chalmers J, et al. Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 2008;39:2226-2230
20. American Heart Association. Stroke warning signs. Available from http://www.americanheart.org/presenter.jhtml?identifier=4742. Accessed March 6, 2010.
21. Centers for Disease Control and Prevention. Prehospital and hospital delays after stroke onset - United States, 2005-2006. MMWR Morb Mortal Wkly Rep 2007;56:474-478
22. Alberts MJ, Latchaw RE, Selman WR, et al. Recommendations for comprehensive stroke centers: a consensus statement from the brain attack coalition. Stroke 2005;36:1597-1616
23. Anonymous. Chapter 2004-325. Committee substitute for Senate Bill No. 1590. Available from http://laws.flrules.org/files/Ch-2004-325.pdf. Accessed October 13, 2009.
24. Lamonte MP, Bahouth MN, Magder LS, et al. A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial. Ann Emerg Med 2009;54:319-327
25. The Internet Stroke Center at Washington University in St. Louis. Stroke scales and clinical assessment tools. Available from http://www.strokecenter. org/trials/scales/index.htm. Accessed October 14, 2009.
26. Demaerschalk BM, Miley ML, Kiernan TE, et al. Stroke telemedicine. Mayo Clin Proc 2009;84:53-64.
27. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health stroke scale: extension to non-neurologists in the context of a clinical trial. Stroke 1997;28:307-310
28. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem 2003;49:1752-1762
29. Millan M, Sobrino T, Castellanos M, et al. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. Stroke 2007;38:90-95
30. Genentech, Inc. Activase (alteplase) package insert. South San Francisco, CA; 2005.
31. Engelter ST, Fluri F, Buitrago-Tellez C, et al. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J Neurol 2005;252:1167-1170
32. Molinaro G, Gervais N, Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke 2002;33:1712-1716
33. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587
34. del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr, on Behalf of the American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. Stroke 2009;40:2945-2948
35. Clark WM, Albers GW, Madden KP, Hamilton S, for the Thromblytic Therapy in Acute Ischemic Stroke Study Investigators. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke 2000;31:811-816
36. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study - a randomized controlled trial (alteplase thrombolysis for acute noninterventional therapy in ischemic stroke). JAMA 1999;282:2019-2026
37. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European cooperative acute stroke study (ECASS). JAMA 1995;274:1017-1025
38. Hacke W, Kaste M, Fieschi C, et al, for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-1251
39. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet 2007;369:275-282 (Erratum in Lancet 2007;369:826.)
40. Saver JL, Gornbein J, Grotta J, et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3 to 4.5 hour window: joint outcome table analysis of the ECASS 3 trial. Stroke 2009;40:2433-2437
41. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303-1309
42. Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome - results of a prospective multicenter study. Stroke 2008;39:2249-2256
43. Bershad EM, Feen ES, Hernandez OH, Suri MF, Suarez JI. Impact of a specialized neurointensive care team on outcomes of critically ill acute ischemic stroke patients. Neurocrit Care 2008;9:287-292
44. Pancioli AM, Broderick J, Brott T, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 2008;39: 3268-3276
45. The Internet Stroke Center at Washington University in St. Louis. CLEAR-ER: study of the combination therapy of rt-PA and eptifibatide to treat acute ischemic stroke (SPOTRIAS). Available from http://www.strokecenter.org/ trials/TrialDetail.aspx?tid=995. Accessed October 14 2009.
46. The IMS Study Investigators. Combined intravenous and intraarterial recanalization for acute ischemic stroke: the interventional management of stroke study. Stroke 2004;35: 904-911
47. The IMS II Trial Investigators. The interventional management of stroke (IMS) II study. Stroke 2007;38:2127-2135
48. Kidwell CS, Saver JL, Carneado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002;33:717-724
49. The Internet Stroke Center at Washington University in St. Louis. IMS-III: the interventional management of stroke (IMS) III trial. Available from http://www.strokecenter.org/trials/TrialDetail.aspx?tid=747. Accessed March 6, 2010.
50. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update - a guideline from the American Heart Association/American Stroke Association stroke council, high blood pressure research council, and the quality of care and outcomes in research interdisciplinary working group. Circulation 2007;116:e391-413.
51. Powner DJ, Hartwell EA, Hoots WK. Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies. Neurosurgery 2005;57:823-831
52. Mattle HP, Arnold M, Georgiadis D, et al. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke 2008;39: 379-383
53. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008;39:1205-1212
54. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001;32:1330-1335
55. Bose A, Henkes H, Alfke K, et al. The penumbra system: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol 2008;29:1409-1413
56. Riedel CH, Tietke M, Alfke K, Stingele R, Jansen O. Subacute stent thrombosis in intracranial stenting. Stroke 2009;40: 1310-1314
57. Donnan GA, Davis SM. Heparin in stroke: not for most, but the controversy lingers. Stroke 2003;34:232-233 (Pubitemid 36070830)
58. Caplan LR. Resolved: heparin may be useful in selected patients with brain ischemia. Stroke 2003;34:230-231
59. Chamorro A, Vila N, Ascaso C, Blanc R. Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment. Arch Neurol 1999;56:1098-1102
60. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008;133(6 suppl):S630-69.
61. Bath PM, Iddenden R, Bath FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke 2000;31:1770-1778 (Pubitemid 30437536)
62. Baird TA, Parsons MW, Barber PA, et al. The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. J Clin Neurosci 2002;9:618-626
63. Yong M, Kaste M. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke 2008;39:2749-2755
64. Finfer S, Chittock DR, Su SY, et al, for the NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360: 1283-1297
65. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772
66. Phillips SJ. Pathophysiology and management of hypertension in acute ischemic stroke. Hypertension 1994;23:131-136 (Pubitemid 24022054)
67. Rose JC, Mayer SA. Optimizing blood pressure in neurological emergencies. Neurocrit Care 2004;1:287-299
68. Potter JF, Robinson TG, Ford GA, et al. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol 2009;8:48-56.
69. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002;33:2123-2136
70. Saver JL, Kidwell C, Eckstein M, Starkman S. Prehospital neuroprotective therapy for acute stroke: results of the field administration of stroke therapy-magnesium (FAST-MAG) pilot trial. Stroke 2004;35:e106-8.
71. Elkind MS, Flint AC, Sciacca RR, Sacco RL. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 2005;65:253-258
72. Amarenco P, Bogousslavsky J, Callahan A III, et al, for the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355: 549-559
73. The Internet Stroke Center at Washington University in St. Louis. NeuSTART II: neuroprotection with statin therapy for acute recovery trial (NeuSTART): a phase 2 safety and pilot efficacy study of lovastatin for the treatment of acute ischemic stroke (SPOTRIAS). Available from http://www.strokecenter.org/trials/TrialDetail.aspx?tid=971. Accessed March 6, 2010.
74. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007;69:904-910
75. ClinicalTrials.gov. Field administration of stroke therapy - magnesium (FAST-MAG) trial. Available from http://clinical trials.gov/ct2/show/ NCT00059332?recr=open&intr=%22Emergency+Medical+Services%22&rank=2. Accessed January 22, 2009.
76. Azzimondi G, Bassein L, Nonino F, et al. Fever in acute stroke worsens prognosis: a prospective study. Stroke 1995;26:2040-2043
77. Krieger DW, De Georgia MA, Abou-Chebl A, et al. Cooling for acute ischemic brain damage (COOL AID): an open pilot study of induced hypothermia in acute ischemic stroke. Stroke 2001;32:1847-1854.
78. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557-563
79. Lyden PD, Allgren RL, Ng K, et al. Intravascular cooling in the treatment of stroke (ICTuS): early clinical experience. J Stroke Cerebrovasc Dis 2005;14:107-114
80. Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med 2009;37(7 suppl):S186-202.
81. Schwab S, Schwarz S, Spranger M, Keller E, Bertram M, Hacke W. Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction. Stroke 1998;29: 2461-2466 (Pubitemid 28543990)
82. Mokhtarani M, Mahgoub AN, Morioka N, et al. Buspirone and meperidine synergistically reduce the shivering threshold. Anesth Analg 2001;93:1233-1239
83. Steiner T, Friede T, Aschoff A, Schellinger PD, Schwab S, Hacke W. Effect and feasibility of controlled rewarming after moderate hypothermia in stroke patients with malignant infarction of the middle cerebral artery. Stroke 2001;32:2833-2835
84. Carandang RA, Krieger DW. Decompressive hemicraniectomy and durotomy for malignant middle cerebral artery infarction. Neurocrit Care 2008;8:286-289
85. Schirmer CM, Ackil AA Jr, Malek AM. Decompressive craniectomy. Neurocrit Care 2008;8:456-470
86. Bardutzky J, Schwab S. Antiedema therapy in ischemic stroke. Stroke 2007;38:3084-3094
87. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007;6:215-222 (Pubitemid 46237760)
88. Mayer SA, Rincon F. Treatment of intracerebral haemorrhage. Lancet Neurol 2005;4:662-672
89. The Internet Stroke Center at Washington University in St. Louis. Stroke interventions in clinical trials: investigational drugs - by name. Available from http://www.strokecenter.org/Trials/index-drugs.aspx. Accessed March 6, 2010.
90. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. Stroke therapy academic industry roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke 2009;40:2594-2600
91. Specialized Programs of Translational Research in Acute Stroke (SPOTRIAS) Network. Available from http://hopecenter.wustl.edu/spotrias/Pages/default. aspx. Accessed March 6, 2010.